Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major antibody categories: those to the acetylcholine receptor (AChR ...

The FDA has approved Alexion's Soliris for use in patients with treatment resistant generalised Myasthenia gravis (gMG), making it the first new therapy for the condition in 60 years. The approval ...

Heightened focus on delays in diagnosing generalized myasthenia gravis (gMG) follows the promise of better results for some patients with newer treatments that include complement inhibitors and ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

Saturday-morning cartoons were legend back in the day. Here are some of the best '80s cartoons that will make you feel like a kid again.

Bears Vyvgart’s initial average price in myasthenia gravis of $225,000 per year per patient in the US could fall over time, as international launches progress and as competitors reach the market.

Matt Davies is Newsday’s Pulitzer Prize-winning editorial cartoonist. Davies is also a children’s book author and illustrator, currently publishing with Macmillan imprint; Neal Porter Books ...

David Rowe is a multiple Walkley award-winning cartoonist. He draws a daily political cartoon and one for the Chanticleer column. David Rowe is a multiple Walkley award-winning cartoonist. He ...

Background Myasthenia gravis (MG) represents a heterogeneous group of autoantibody-mediated diseases targeting the neuromuscular junction. Extraocular muscles (EOMs) are highly susceptible to ...

Every cartoon from The New Yorker.A drawing that riffs on the latest news and happenings.